Phase I/II study to evaluate the safety and efficacy of intrathecal injection of KP-100IT in subjects with acute spinal cord injury
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs KP 100IT (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kringle Pharma
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 27 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Oct 2018.